A multicenter, single arm, post-marketing surveillance study. This study is a postlicensure requirement of the Korea Food and Drug Administration (KFDA) to provide continued safety evaluation of MenACWY in the Korean population from 2 months to 55 years of age, receiving MenACWY-CRM vaccination according to routine clinical practice and prescribing information.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
3,948
One dose administered intramuscularly preferably into the anterolateral aspect of the thigh in infants or into the deltoid muscle in children, adolescents and adults.
Number of Subjects Reporting Any Local and Systemic Solicited Adverse Events (AEs)
Assessed solicited local AEs include: injection site erythema, injection site induration, injection site tenderness, injection site pain. Assessed solicited systemic AEs include: change in eating habits, sleepiness, irritability, rash, vomiting, diarrhea, fever, chills, nausea, malaise, generalized myalgia, generalized arthralgia, headache. "Any" is defined as any report of the specified symptom irrespective of intensity grade. Subjects from 2 months to 55 years of age were evaluated for the outcome measure.
Time frame: From Day 1 of vaccination to Day 7 post vaccination
Number of Subjects Reporting Any Unsolicited Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with this treatment. All unsolicited AEs reported from day 1 to day 7 post vaccination were assessed. "Any" is defined as any report of the specified symptom irrespective of intensity grade. Subjects from 2 months to 55 years of age were evaluated for the outcome measure.
Time frame: From Day 1 of vaccination to Day 7 post vaccination
Number of Subjects Reporting Medically Attended AEs (MAAEs)
MAAEs are defined as events that require a physician's visit or an emergency room visit. All reported MAAEs from day 1 to day 29 were assessed. Subjects from 2 months to 55 years of age were evaluated for the outcome measure.
Time frame: From Day 1 of vaccination to study termination (Day 29/early termination)
Number of Subjects Reporting Serious AEs (SAEs)
An SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening (i.e., the subject was, in the opinion of the investigator, at immediate risk of death from the event as it occurred); it does not refer to an event which hypothetically might have caused death if it were more severe, requires or prolongs subject's hospitalization, results in persistent or significant disability/incapacity (i.e., the event causes a substantial disruption of a person's ability to conduct normal life functions), results in a congenital anomaly/birth defect, is an important and significant medical event that may not be immediately life threatening or resulting in death or hospitalization but, based upon appropriate medical judgment, may jeopardize the subject or may require intervention to prevent one of the other outcomes listed above. Subjects from 2 months to 55 years of age were evaluated for the outcome measure.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
GSK Investigational Site
Ansan, South Korea
GSK Investigational Site
Anyang, South Korea
GSK Investigational Site
Bucheon-si, South Korea
GSK Investigational Site
Busan, South Korea
GSK Investigational Site
Changwon, South Korea
GSK Investigational Site
Daegu, South Korea
GSK Investigational Site
Daejeon, South Korea
GSK Investigational Site
Daejeon, South Korea
GSK Investigational Site
Donghae, South Korea
GSK Investigational Site
Gimhae, South Korea
...and 44 more locations
Time frame: From Day 1 of vaccination to study termination (Day 29/early termination)